Indaptus Therapeutics (INDP) Competitors $1.05 -0.01 (-0.99%) (As of 10:15 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends INDP vs. RLYB, DYAI, VRCA, RVPH, CERO, CVM, BRNS, OSTX, ANEB, and LUMOShould you be buying Indaptus Therapeutics stock or one of its competitors? The main competitors of Indaptus Therapeutics include Rallybio (RLYB), Dyadic International (DYAI), Verrica Pharmaceuticals (VRCA), Reviva Pharmaceuticals (RVPH), CERo Therapeutics (CERO), CEL-SCI (CVM), Barinthus Biotherapeutics (BRNS), OS Therapies (OSTX), Anebulo Pharmaceuticals (ANEB), and Lumos Pharma (LUMO). These companies are all part of the "pharmaceutical products" industry. Indaptus Therapeutics vs. Rallybio Dyadic International Verrica Pharmaceuticals Reviva Pharmaceuticals CERo Therapeutics CEL-SCI Barinthus Biotherapeutics OS Therapies Anebulo Pharmaceuticals Lumos Pharma Indaptus Therapeutics (NASDAQ:INDP) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, earnings, valuation, profitability, dividends, media sentiment and institutional ownership. Do analysts recommend INDP or RLYB? Indaptus Therapeutics presently has a consensus price target of $8.50, indicating a potential upside of 709.91%. Rallybio has a consensus price target of $9.75, indicating a potential upside of 875.00%. Given Rallybio's higher possible upside, analysts plainly believe Rallybio is more favorable than Indaptus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Rallybio 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has more volatility & risk, INDP or RLYB? Indaptus Therapeutics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.67, suggesting that its stock price is 267% less volatile than the S&P 500. Does the MarketBeat Community believe in INDP or RLYB? Rallybio received 26 more outperform votes than Indaptus Therapeutics when rated by MarketBeat users. However, 86.67% of users gave Indaptus Therapeutics an outperform vote while only 76.47% of users gave Rallybio an outperform vote. CompanyUnderperformOutperformIndaptus TherapeuticsOutperform Votes1386.67% Underperform Votes213.33%RallybioOutperform Votes3976.47% Underperform Votes1223.53% Which has better earnings and valuation, INDP or RLYB? Rallybio is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIndaptus TherapeuticsN/AN/A-$15.42M-$1.71-0.61RallybioN/AN/A-$74.56M-$1.60-0.62 Is INDP or RLYB more profitable? Rallybio's return on equity of -77.39% beat Indaptus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Indaptus TherapeuticsN/A -177.27% -141.06% Rallybio N/A -77.39%-69.33% Do insiders & institutionals believe in INDP or RLYB? 7.1% of Indaptus Therapeutics shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 29.5% of Indaptus Therapeutics shares are owned by insiders. Comparatively, 7.4% of Rallybio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media prefer INDP or RLYB? In the previous week, Indaptus Therapeutics had 1 more articles in the media than Rallybio. MarketBeat recorded 1 mentions for Indaptus Therapeutics and 0 mentions for Rallybio. Indaptus Therapeutics' average media sentiment score of 0.28 beat Rallybio's score of 0.00 indicating that Indaptus Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Indaptus Therapeutics Neutral Rallybio Neutral SummaryIndaptus Therapeutics beats Rallybio on 8 of the 15 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Indaptus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INDP vs. The Competition Export to ExcelMetricIndaptus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.71M$6.48B$5.07B$8.80BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-0.614.9789.5613.60Price / SalesN/A371.451,224.8087.40Price / CashN/A52.5939.4536.27Price / Book1.7810.306.976.33Net Income-$15.42M$153.61M$119.04M$225.93M7 Day Performance-6.71%-1.73%-1.78%-0.96%1 Month Performance-28.61%-7.26%-3.59%1.06%1 Year Performance-49.78%31.10%31.64%26.59% Indaptus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INDPIndaptus Therapeutics2.7304 of 5 stars$1.05-1.0%$8.50+709.9%-48.7%$10.71MN/A-0.616RLYBRallybio2.5309 of 5 stars$1.00+0.6%$9.75+875.0%-59.4%$41.49MN/A0.0040DYAIDyadic International2.1296 of 5 stars$1.39-7.0%$6.00+333.2%-17.7%$40.98M$2.90M-5.657Analyst RevisionVRCAVerrica Pharmaceuticals4.575 of 5 stars$0.88-0.7%$9.60+989.7%-76.1%$40.17M$5.12M0.0040News CoverageRVPHReviva Pharmaceuticals2.6308 of 5 stars$1.20-1.3%$15.50+1,192.1%-71.1%$40.12MN/A0.005CEROCERo TherapeuticsN/A$0.27+6.5%N/AN/A$39.83MN/A0.008Gap DownCVMCEL-SCIN/A$0.62-1.6%N/A-74.0%$39.45MN/A0.0043Analyst DowngradeBRNSBarinthus Biotherapeutics1.658 of 5 stars$0.99+10.1%$5.83+489.2%-69.1%$39.15M$800,000.00-0.60107Analyst ForecastGap UpOSTXOS TherapiesN/A$1.84+6.6%N/AN/A$39.08MN/A0.00N/AANEBAnebulo Pharmaceuticals2.5011 of 5 stars$1.49-2.0%$8.00+436.9%-30.9%$38.64MN/A0.004Analyst ForecastShort Interest ↓News CoverageGap UpLUMOLumos Pharma3.2177 of 5 stars$4.34+0.5%$8.63+98.7%+41.2%$37.54M$2.05M0.0030 Related Companies and Tools Related Companies RLYB Alternatives DYAI Alternatives VRCA Alternatives RVPH Alternatives CERO Alternatives CVM Alternatives BRNS Alternatives OSTX Alternatives ANEB Alternatives LUMO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INDP) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indaptus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Indaptus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
